Clearmind Completed Treatment And Follow-Up For 18 Participants In CMND-100 Trial For AUD

Clearmind reported completion of treatment and follow-up for 18 participants in its ongoing Phase 1/2a trial of CMND-100, a non-hallucinogenic MEAI-based oral candidate for Alcohol Use Disorder. The milestone de-risks very early-stage development but is limited by a small sample (n=18); next steps are data analysis and potential progression to later cohorts or phases. Near-term market impact should be minimal, though the update may modestly support investor interest in the company's clinical progress.

Analysis

Clearmind reported completion of treatment and follow-up for 18 participants in its ongoing Phase 1/2a trial of CMND-100, a non-hallucinogenic MEAI-based oral candidate for Alcohol Use Disorder. The milestone de-risks very early-stage development but is limited by a small sample (n=18); next steps are data analysis and potential progression to later cohorts or phases. Near-term market impact should be minimal, though the update may modestly support investor interest in the company's clinical progress.